Acute Coronary Syndromes
These meetings are intended for UK Healthcare Professionals and have been developed in accordance with the ABPI Code of Practice.
PM Healthcare events are Quality Assured by the University of Bradford
| Satellite | Acute Coronary Syndromes | |||
| Speakers | Steve McGlynn, Specialist Principal Pharmacist (Cardiology), NHS Greater Glasgow and Clyde | |||
| Satellite Description | ||||
|
Pharmacological Management of Acute Coronary Syndromes Coronary Heart Disease (CHD) remains the most common cause of death in the Western World and is a major cause of premature death. Mortality rates are however falling, largely due to improvements in lifestyle and in the early intervention of acute events. Although much of the focus on the management of acute coronary syndromes (ACS) centres on percutaneous coronary intervention, pharmacological interventions remain a key component of managing the acute event and secondary prevention. Acutely, medical management is aimed at restoration of coronary blood flow and reducing ischaemia. Subsequently patients are at risk of developing complications of myocardial damage and of disease progression. Unlike primary prevention, no formal risk assessment is performed. Patients with existing disease, and patients with diabetes, are automatically considered high risk and should be considered for secondary prevention strategies. Whilst the acute management will largely be delivered by hospital services, the chronic disease management aspect will largely be delivered by Primary Care. Both NICE and SIGN have produced guidance on the both the acute and chronic management of ACS. This session with explore the evidence-base behind the guidance and consider some of the practical aspects of secondary prevention. | ||||
